International Journal of Neonatal Screening (Aug 2022)

Expanded Newborn Screening in Italy Using Tandem Mass Spectrometry: Two Years of National Experience

  • Margherita Ruoppolo,
  • Sabrina Malvagia,
  • Sara Boenzi,
  • Carla Carducci,
  • Carlo Dionisi-Vici,
  • Francesca Teofoli,
  • Alberto Burlina,
  • Antonio Angeloni,
  • Tommaso Aronica,
  • Andrea Bordugo,
  • Ines Bucci,
  • Marta Camilot,
  • Maria Teresa Carbone,
  • Roberta Cardinali,
  • Claudia Carducci,
  • Michela Cassanello,
  • Cinzia Castana,
  • Chiara Cazzorla,
  • Renzo Ciatti,
  • Simona Ferrari,
  • Giulia Frisso,
  • Silvia Funghini,
  • Francesca Furlan,
  • Serena Gasperini,
  • Vincenza Gragnaniello,
  • Chiara Guzzetti,
  • Giancarlo La Marca,
  • Luisa La Spina,
  • Tania Lorè,
  • Concetta Meli,
  • MariaAnna Messina,
  • Amelia Morrone,
  • Francesca Nardecchia,
  • Rita Ortolano,
  • Giancarlo Parenti,
  • Enza Pavanello,
  • Damiana Pieragostino,
  • Sara Pillai,
  • Francesco Porta,
  • Francesca Righetti,
  • Claudia Rossi,
  • Valentina Rovelli,
  • Alessandro Salina,
  • Laura Santoro,
  • Pina Sauro,
  • Maria Cristina Schiaffino,
  • Simonetta Simonetti,
  • Monica Vincenzi,
  • Elisabetta Tarsi,
  • Anna Paola Uccheddu

DOI
https://doi.org/10.3390/ijns8030047
Journal volume & issue
Vol. 8, no. 3
p. 47

Abstract

Read online

Newborn screening (NBS) for inborn errors of metabolism is one of the most advanced tools for secondary prevention in medicine, as it allows early diagnosis and prompt treatment initiation. The expanded newborn screening was introduced in Italy between 2016 and 2017 (Law 167/2016; DM 13 October 2016; DPCM 12-1-2017). A total of 1,586,578 infants born in Italy were screened between January 2017 and December 2020. For this survey, we collected data from 15 Italian screening laboratories, focusing on the metabolic disorders identified by tandem mass spectrometry (MS/MS) based analysis between January 2019 and December 2020. Aminoacidemias were the most common inborn errors in Italy, and an equal percentage was observed in detecting organic acidemias and mitochondrial fatty acids beta-oxidation defects. Second-tier tests are widely used in most laboratories to reduce false positives. For example, second-tier tests for methylmalonic acid and homocysteine considerably improved the screening of CblC without increasing unnecessary recalls. Finally, the newborn screening allowed us to identify conditions that are mainly secondary to a maternal deficiency. We describe the goals reached since the introduction of the screening in Italy by exchanging knowledge and experiences among the laboratories.

Keywords